Aviado · Research
Longevity Daily
Tuesday, June 9, 2026
Listen
Today's Brief
Today's lead story is the first human injection of an epigenetic reprogramming therapy — a genuine milestone that moves cellular rejuvenation from theory to clinical reality. David Sinclair's simultaneous XPrize announcement confirms the field is accelerating fast, while a new study finds GLP-1 receptor agonists cut dementia and Alzheimer's risk more effectively than metformin. Fight Aging surfaces compelling genetic evidence that PAI-1 inhibitors could be a serious longevity drug, and new preclinical data raises underappreciated questions about what happens to cellular aging after GLP-1 treatment ends.
10 stories1 peer-reviewed
Cognitive Health & Neuroprotection
GLP-1 Receptor Agonists Beat Metformin at Protecting the Brain Against Dementia
A new observational study finds that GLP-1 receptor agonists — the drug class behind semaglutide and tirzepatide — reduce overall dementia risk more effectively than metformin in people with type 2 diabetes, with particularly strong protection against Alzheimer's disease and non-vascular dementias. The mechanism likely goes beyond blood sugar control; GLP-1 receptors are expressed throughout the brain, and researchers suspect direct neuroprotective effects are at work. If you're managing blood sugar and have cognitive longevity as a priority, this adds meaningful weight to the GLP-1 case.
Read more →Supplements & Compounds
Urolithin A Restores Cellular Power Networks Through a Newly Mapped Mitophagy Pathway
A new study in Current Neuropharmacology identifies the specific calcium-dependent mechanism through which Urolithin A — a compound derived from pomegranates and increasingly popular as a longevity supplement — triggers mitophagy and restores coordination between mitochondria, the endoplasmic reticulum, and lysosomes in aging cells. The research was conducted in nematodes and mammalian cells (not humans), but it provides one of the clearest mechanistic explanations yet for why Urolithin A shows promise for cellular aging and neuroprotection. If you're already taking Urolithin A, this is the science behind why it may be working.
Read more →Research & Papers
History Made: First Epigenetic Reprogramming Therapy Injected Into a Living Human
For the first time, a therapy designed to use epigenetic reprogramming — resetting gene-expression patterns in aging cells to make them act younger — has been injected into a living human. The treatment was originally cleared by the FDA for optic nerve conditions, but the underlying technology, partial cellular reprogramming, is the same mechanism longevity researchers have been building toward for a decade. This is the field's most significant translational milestone to date: moving from dramatic results in animal models to actual human data. The results of this trial will be closely watched by everyone from academic researchers to the world's largest pharmaceutical companies.
Read more →Continuous Low-Dose Rapamycin Favorably Reshapes Immune Aging in Mice
A new mouse study finds that when rapamycin is delivered continuously through the diet — rather than the weekly pulse dose common among human longevity users — it significantly alters aging immune dynamics, reducing chronic inflammation and partially reversing hallmarks of immunosenescence. The mTOR pathway is the central mechanism, and the findings suggest that delivery method may matter as much as dose for achieving immune benefits. This is animal-only data and translating it to human protocols remains an open question, but it's directly relevant to the growing population exploring low-dose rapamycin.
Read more →People Born With This Rare Mutation Live 7 Years Longer — and a Drug Is in Development
Rare individuals who carry a loss-of-function mutation in PAI-1 live up to seven years longer than their peers — and researchers have linked this advantage to reduced cellular senescence, making PAI-1 inhibition one of the more biologically credible longevity targets in drug development. Small molecule inhibitors are now in active development, and while a drug will never fully replicate a lifelong genetic head start, this review covers how close the field is getting. Worth tracking as a next-generation senolytics-adjacent compound.
Read more →Can Therapeutic Plasma Exchange Actually Remove Microplastics? A New Study Weighs In
A new study suggests therapeutic plasma exchange (TPE) may offer a way to reduce microplastics in the body — a finding arriving just as the procedure surges in longevity and biohacking circles, with users including Bryan Johnson, Gwyneth Paltrow, and Troy Aikman. Axios examines both what the emerging evidence shows and the significant gap between the science and the hype surrounding TPE as a 'healthspan' intervention. Before booking a session, this is the most grounded overview of what we actually know.
Read more →A Father's Pre-Conception Drinking Damages His Children's Mitochondria — Epigenetically
A new study finds that alcohol exposure in fathers before conception transmits epigenetic damage to offspring mitochondria, potentially increasing their children's risk of chronic disease and accelerating biological aging without altering the underlying DNA sequence. The mechanism is transgenerational — meaning the damage can persist beyond the directly exposed generation. While human data is still limited, the findings underscore that preconception health in men is a meaningful and underappreciated lever for the long-term health of their children.
Read more →Lifestyle & Nutrition
Harvard's Landmark Study Settles the Cardio vs. Strength Training Debate for Longevity
A major Harvard-led study published in the British Journal of Sports Medicine delivers a data-backed verdict on whether cardio or strength training is more effective for reducing mortality risk and extending lifespan, resolving one of fitness's most persistent debates with a sample large enough to be taken seriously. For longevity-focused exercisers, this provides clearer guidance on where to prioritize training time. Note that while the underlying BJSM research carries the scientific weight, this summary is via Times of India — check the primary study for full methodology.
Read more →Industry & Policy
David Sinclair Enters Whole-Body Rejuvenation Drugs Into XPrize to Prove They Work
David Sinclair is entering his whole-body rejuvenation drug protocols into the XPrize competition, framing it as the first opportunity for structured, comparative testing of whether these therapies can make someone measurably younger. The XPrize format introduces accountability — measurable outcomes, independent evaluation — largely absent from current longevity drug claims. Paired with today's news of the first human reprogramming injection, this signals a new, more testable phase of longevity science.
Read more →After GLP-1 Treatment Ends, What Happens to Your Cells? New Data Raises Hard Questions
Preclinical findings from senolytic company Eos SENOLYTIX, presented at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum, suggest that the biology of how weight is lost on GLP-1 drugs — and what happens to cellular aging markers after treatment stops — may matter more than the scale number itself. The analysis raises concerns about senescent cell burden and muscle loss that standard GLP-1 trials are not designed to detect. This is early preclinical data from a company with an obvious interest, but the questions being asked are important ones for the millions now on long-term GLP-1 therapy.
Read more →